SI3354273T1 - Melanokortinski receptor ligandi - Google Patents

Melanokortinski receptor ligandi

Info

Publication number: SI3354273T1
Authority: SI; Slovenia
Prior art keywords: receptor ligands; melanocortin receptor; melanocortin; ligands; receptor
Prior art date: 2005-07-08

Application number

SI200632406T

Other languages

English (en)

Inventor

Zheng Xin Dong

Jacques-Pierre Moreau

Original Assignee

Ipsen Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-08

Filing date

2006-07-10

Publication date

2021-10-29

2006-07-10 Application filed by Ipsen Pharma filed Critical Ipsen Pharma

2021-10-29 Publication of SI3354273T1 publication Critical patent/SI3354273T1/sl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)

SI200632406T 2005-07-08 2006-07-10 Melanokortinski receptor ligandi SI3354273T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US69777905P	2005-07-08	2005-07-08
US74885005P	2005-12-09	2005-12-09
EP17202836.7A EP3354273B1 (en)	2005-07-08	2006-07-10	Melanocortin receptor ligands

Publications (1)

Publication Number	Publication Date
SI3354273T1 true SI3354273T1 (sl)	2021-10-29

Family

ID=37637790

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200632406T SI3354273T1 (sl)	2005-07-08	2006-07-10	Melanokortinski receptor ligandi

Country Status (21)

Country	Link
US (8)	US8039435B2 (sl)
EP (6)	EP2548568B1 (sl)
JP (4)	JP4734411B2 (sl)
KR (2)	KR100997177B1 (sl)
CN (4)	CN103755786B (sl)
AU (2)	AU2006269261B2 (sl)
CA (4)	CA2614615C (sl)
DK (4)	DK2548568T3 (sl)
ES (4)	ES2663916T3 (sl)
FR (1)	FR21C1060I2 (sl)
HK (2)	HK1149190A1 (sl)
HU (4)	HUE031731T2 (sl)
IL (3)	IL188545A (sl)
NL (1)	NL301150I2 (sl)
NZ (2)	NZ565217A (sl)
PL (4)	PL2236151T3 (sl)
PT (4)	PT3354273T (sl)
RU (2)	RU2439079C2 (sl)
SG (1)	SG163585A1 (sl)
SI (1)	SI3354273T1 (sl)
WO (1)	WO2007008704A2 (sl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102007020152A1 (de) *	2007-04-26	2008-10-30	Charité - Universitätsmedizin Berlin	Mittel zur antiinfektiven Behandlung eines Patienten
TWI364290B (en) *	2007-05-25	2012-05-21	Ipsen Pharma Sas	Melanocortin receptor ligands modifled with hydantoin
TW200848424A (en) *	2007-06-15	2008-12-16	Sod Conseils Rech Applic	Cyclic peptide melanocortin receptor ligands
ES2555522T3 (es) *	2007-11-05	2016-01-04	Ipsen Pharma S.A.S.	Uso de melanocortinas para tratar la sensibilidad a la insulina
KR20170102050A (ko) *	2008-05-27	2017-09-06	젠자임 코포레이션	알파-멜라노사이트 자극 호르몬의 펩티드 유사체
MX2010013436A (es)	2008-06-09	2011-06-21	Palatin Technologies Inc	Peptidos especificos del receptor de melanocortina para el tratamiento de disfuncion sexual.
WO2010144341A2 (en)	2009-06-08	2010-12-16	Palatin Technologies, Inc.	Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es)	2009-06-08	2011-01-31	Astrazeneca Ab	Péptidos específicos para receptores de melanocortina
MX2011013117A (es)	2009-06-08	2012-05-23	Palatin Technologies Inc	Peptidos especificos del receptor de melanocortina.
IN2012DN01493A (sl) *	2009-08-05	2015-06-05	Ipsen Pharma Sas
DK2473518T3 (en) *	2009-08-31	2017-03-27	Tensive Controls Inc	Stabilized melanocortin ligands
RU2012125033A (ru) *	2009-11-16	2014-01-20	Ипсен Фарма С.А.С.	СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
ES2654147T3 (es) *	2009-11-16	2018-02-12	Ipsen Pharma S.A.S.	Composiciones farmacéuticas de ligandos del receptor de melanocortina
WO2011063366A1 (en)	2009-11-23	2011-05-26	Palatin Technologies, Inc.	Melanocortin-1 receptor-specific cyclic peptides
BR112012011780A2 (pt)	2009-11-23	2019-09-24	Palatin Technologies, Inc	peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
RU2633483C2 (ru) *	2011-06-14	2017-10-12	Ипсен Фарма С.А.С.	Композиция с длительным высвобождением, содержащая в качестве активного ингредиента пептиды
HUE056948T2 (hu)	2011-12-29	2022-04-28	Rhythm Pharmaceuticals Inc	Melanokortin-4 receptorral összefüggõ rendellenességek kezelési módszere heterozigóta hordozókban
EP2705835A1 (en)	2012-06-08	2014-03-12	Ipsen Pharma S.A.S.	Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
CA2888277C (en) *	2012-10-19	2023-09-05	Txp Pharma Gmbh	Alpha- and gamma-msh analogues
US10232018B2 (en)	2013-03-14	2019-03-19	Mallinckrodt Ard Ip Limited	ACTH for treatment of acute respiratory distress syndrome
JP6622690B2 (ja) *	2013-03-15	2019-12-18	リズム・ファーマシューティカルズ・インコーポレイテッド	ペプチド組成物
CN115957297A (zh) *	2013-03-15	2023-04-14	节奏制药公司	药物组合物
AU2015249540B2 (en)	2014-04-22	2019-08-22	Txp Pharma Gmbh	Peptide analogues with branched amino acid probe(s)
AU2016330773A1 (en)	2015-09-30	2018-04-19	Charité-Universitätsmedizin Berlin	Method of treating melanocortin-4 receptor pathway-associated disorders
US11542302B2 (en)	2015-10-15	2023-01-03	Arizona Board Of Regents On Behalf Of The University Of Arizona	Modulators of melanocortin receptors for the treatment of depression and anxiety
WO2017066754A1 (en) *	2015-10-15	2017-04-20	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Compositions and methods for the treatment of depression and anxiety
US20190255142A1 (en) *	2016-10-17	2019-08-22	Arizona Board Of Regents On Behalf Of The University Of Arizona	Novel modulators of melanocortin receptors for the treatment of depression and anxiety
JP2020514365A (ja) *	2017-03-15	2020-05-21	ノヴォノルディスクアー／エス	メラノコルチン４受容体に結合可能な二環式化合物
EP3773897A1 (en)	2018-04-06	2021-02-17	Rhythm Pharmaceuticals, Inc.	Compositions for treating kidney disease
US20210221867A1 (en) *	2018-05-15	2021-07-22	Novo Nordisk A/S	Compounds Capable of Binding to Melanocortin 4 Receptor
US11396535B2 (en)	2019-03-01	2022-07-26	Provincial Health Services Authority	Cyclic peptide analogs of melanocortin and amanitin and methods of making such
TW202228760A (zh) *	2020-09-24	2022-08-01	美商律森製藥股份有限公司	治療黑素皮質素-4受體路徑相關病症之方法
EP4347019A1 (en) *	2021-05-27	2024-04-10	The Regents Of The University Of Michigan	Mc3r agonist peptides
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US613874A (en)		1898-11-08		George e
US1613874A (en)	1922-03-29	1927-01-11	Miner Inc W H	Friction draft gear
US5652214A (en)	1989-06-05	1997-07-29	Cephalon, Inc.	Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en)	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
US5665702A (en)	1995-06-06	1997-09-09	Biomeasure Incorporated	Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en)	1996-11-01	1999-06-29	Poly-Med, Inc.	Acylated cyclodextrin derivatives
SE9700620D0 (sv)	1997-02-21	1997-02-21	Wapharm Ab	Cykliska peptider med selektivitet för MSH-receptor subtyper
AU7464998A (en)	1997-10-27	1999-05-17	Trega Biosciences, Inc.	Melanocortin receptor ligands and methods of using same
EP1076649A4 (en)	1998-04-28	2010-06-02	Trega Biosciences Inc	ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
WO2000006777A2 (en) *	1998-07-27	2000-02-10	Iowa State University Research Foundation, Inc.	Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals
EP1119252A4 (en)	1998-08-21	2004-03-03	Childrens Medical Center	USE OF MELANIN FOR INHIBITING ANGIOGENESIS AND MACULAR DEGENERATION
US6716810B1 (en)	1998-12-09	2004-04-06	Eleanor Roosevelt Institute	Composition and method for regulation of body weight and associated conditions
US6603058B1 (en)	1998-12-09	2003-08-05	Oklahoma Medical Research Foundation	Non-human animal model for obesity and uses thereof
KR100519201B1 (ko)	1999-03-29	2005-10-06	더 프록터 앤드 갬블 캄파니	멜라노코르틴 수용체 리간드
US7176279B2 (en)	2000-06-28	2007-02-13	Palatin Technologies, Inc.	Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) *	1999-06-29	2003-06-17	Palatin Technologies, Inc.	Compositions and methods for treatment of sexual dysfunction
JP2003513645A (ja)	1999-11-12	2003-04-15	メルクエンドカムパニーインコーポレーテッド	メラノコルチン−３レセプター欠失細胞、非ヒトトランスジェニック動物及び体重を調節する化合物の選択方法
US6600015B2 (en)	2000-04-04	2003-07-29	Hoffmann-La Roche Inc.	Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
KR20030017571A (ko) *	2000-06-28	2003-03-03	화이자 프로덕츠 인크.	멜라노코르틴 수용체 리간드
US6720324B2 (en)	2000-07-05	2004-04-13	Synaptic Pharmaceutical Corporation	Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
EP1322954A4 (en)	2000-09-13	2005-08-03	Eleanor Roosevelt Inst	METHOD FOR TREATING INSULIN RESISTANCE IN OVERWEIGHT AND DIABETES
US20030113263A1 (en)	2001-02-13	2003-06-19	Oregon Health And Sciences University, A Non-Profit Organization	Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
JP2004532838A (ja)	2001-03-02	2004-10-28	ブリストル−マイヤーズスクイブカンパニー	メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物
US6770645B2 (en) *	2001-03-16	2004-08-03	Pfizer Inc.	Pharmaceutically active compounds
IL159797A0 (en) *	2001-07-11	2004-06-20	Palatin Technologies Inc	Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) *	2002-05-07	2006-04-25	University Of Florida	Peptides and methods for the control of obesity
US20040128136A1 (en) *	2002-09-20	2004-07-01	Irani Pourang Polad	Internet voice browser
US20060293223A1 (en) *	2003-06-19	2006-12-28	Eli Lilly And Company Patent Division	Uses of melanocortin-3 receptor (mc3r) agonist peptides
KR20060014444A (ko) *	2003-06-19	2006-02-15	일라이 릴리 앤드 캄파니	멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도
US7084111B2 (en)	2003-06-23	2006-08-01	University Of Florida Research Foundation, Inc.	Melanocortin receptor templates, peptides, and use thereof
ATE361294T1 (de)	2003-08-20	2007-05-15	Lilly Co Eli	Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
DE602004004156T2 (de)	2003-08-20	2007-10-11	Eli Lilly And Co., Indianapolis	Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids
WO2005040109A1 (en) *	2003-10-22	2005-05-06	Neurocrine Biosciences, Inc.	Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de)	2003-11-21	2005-06-23	Orthogen Ag	Transskin
WO2005060985A1 (en)	2003-12-10	2005-07-07	Merck & Co., Inc.	Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
US20070123453A1 (en)	2004-03-29	2007-05-31	Heiman Mark L	Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
JP5449673B2 (ja)	2004-10-08	2014-03-19	クリヌベール、ファーマスーティカルズ、リミテッド	対象者におけるメラニン形成を誘導するための組成物および方法
WO2006073771A2 (en)	2005-01-05	2006-07-13	Eli Lilly And Company	Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073772A1 (en)	2005-01-05	2006-07-13	Eli Lilly And Company	Polyethylene glycol linked mc4r or mc3r agonist peptides
CA2620228C (en)	2005-08-26	2014-12-09	Action Pharma A/S	Therapeutically active .alpha.-msh analogues

2006
- 2006-07-10 RU RU2009131092/04A patent/RU2439079C2/ru active
- 2006-07-10 CN CN201310495024.4A patent/CN103755786B/zh active Active
- 2006-07-10 CA CA2614615A patent/CA2614615C/en active Active
- 2006-07-10 JP JP2008520417A patent/JP4734411B2/ja active Active
- 2006-07-10 EP EP12188784.8A patent/EP2548568B1/en active Active
- 2006-07-10 ES ES12188784.8T patent/ES2663916T3/es active Active
- 2006-07-10 NZ NZ565217A patent/NZ565217A/en unknown
- 2006-07-10 EP EP17202836.7A patent/EP3354273B1/en active Active
- 2006-07-10 CN CN2006800324235A patent/CN101257916B/zh active Active
- 2006-07-10 PT PT172028367T patent/PT3354273T/pt unknown
- 2006-07-10 CN CN200910174061A patent/CN101676298A/zh active Pending
- 2006-07-10 HU HUE10182566A patent/HUE031731T2/en unknown
- 2006-07-10 AU AU2006269261A patent/AU2006269261B2/en active Active
- 2006-07-10 US US11/988,533 patent/US8039435B2/en active Active
- 2006-07-10 DK DK12188784.8T patent/DK2548568T3/en active
- 2006-07-10 HU HUE17202836A patent/HUE055154T2/hu unknown
- 2006-07-10 CA CA3228910A patent/CA3228910A1/en active Pending
- 2006-07-10 NZ NZ580806A patent/NZ580806A/en not_active Application Discontinuation
- 2006-07-10 DK DK17202836.7T patent/DK3354273T3/da active
- 2006-07-10 ES ES10170694T patent/ES2386862T3/es active Active
- 2006-07-10 PL PL10170694T patent/PL2236151T3/pl unknown
- 2006-07-10 EP EP21163411.8A patent/EP3925614A3/en active Pending
- 2006-07-10 PL PL10182566T patent/PL2286825T3/pl unknown
- 2006-07-10 PT PT10170694T patent/PT2236151E/pt unknown
- 2006-07-10 KR KR1020087002955A patent/KR100997177B1/ko active IP Right Grant
- 2006-07-10 PT PT121887848T patent/PT2548568T/pt unknown
- 2006-07-10 ES ES17202836T patent/ES2877349T3/es active Active
- 2006-07-10 CA CA2793119A patent/CA2793119C/en active Active
- 2006-07-10 ES ES10182566.9T patent/ES2604328T3/es active Active
- 2006-07-10 RU RU2008104803/04A patent/RU2380372C2/ru active
- 2006-07-10 DK DK10170694.3T patent/DK2236151T3/da active
- 2006-07-10 EP EP10182566.9A patent/EP2286825B1/en active Active
- 2006-07-10 KR KR1020097022845A patent/KR101232201B1/ko active IP Right Grant
- 2006-07-10 EP EP06786665A patent/EP1915167A4/en not_active Withdrawn
- 2006-07-10 SG SG201004921-1A patent/SG163585A1/en unknown
- 2006-07-10 SI SI200632406T patent/SI3354273T1/sl unknown
- 2006-07-10 EP EP10170694A patent/EP2236151B1/en active Active
- 2006-07-10 CA CA3044795A patent/CA3044795A1/en not_active Abandoned
- 2006-07-10 HU HUE12188784A patent/HUE037147T2/hu unknown
- 2006-07-10 CN CN201610168908.2A patent/CN105837661A/zh active Pending
- 2006-07-10 PL PL17202836T patent/PL3354273T3/pl unknown
- 2006-07-10 PL PL12188784T patent/PL2548568T3/pl unknown
- 2006-07-10 DK DK10182566.9T patent/DK2286825T3/en active
- 2006-07-10 PT PT101825669T patent/PT2286825T/pt unknown
- 2006-07-10 WO PCT/US2006/026586 patent/WO2007008704A2/en active Application Filing
2008
- 2008-01-02 IL IL188545A patent/IL188545A/en active IP Right Grant
- 2008-09-18 HK HK11103282.8A patent/HK1149190A1/xx unknown
2009
- 2009-10-25 IL IL201732A patent/IL201732A/en active IP Right Grant
- 2009-10-28 AU AU2009230799A patent/AU2009230799B2/en active Active
- 2009-11-19 JP JP2009263603A patent/JP5889513B2/ja active Active
2011
- 2011-03-29 US US13/074,565 patent/US9458195B2/en active Active
2013
- 2013-08-08 JP JP2013165312A patent/JP2013253090A/ja active Pending
2015
- 2015-07-14 JP JP2015140154A patent/JP5965520B2/ja active Active
2016
- 2016-06-22 IL IL246392A patent/IL246392A/en active IP Right Grant
- 2016-09-07 US US15/257,970 patent/US20160368962A1/en not_active Abandoned
2017
- 2017-05-05 US US15/587,426 patent/US9850280B2/en active Active
- 2017-12-04 US US15/830,038 patent/US20180105557A1/en not_active Abandoned
2018
- 2018-07-09 US US16/029,837 patent/US20180305406A1/en not_active Abandoned
2019
- 2019-01-28 HK HK19101447.6A patent/HK1258965A1/zh unknown
- 2019-12-04 US US16/702,661 patent/US20200095281A1/en not_active Abandoned
2021
- 2021-12-06 NL NL301150C patent/NL301150I2/nl unknown
- 2021-12-14 FR FR21C1060C patent/FR21C1060I2/fr active Active
- 2021-12-15 HU HUS2100054C patent/HUS2100054I1/hu unknown
2022
- 2022-01-10 US US17/572,115 patent/US20220127305A1/en active Pending

Also Published As

Publication number	Publication date
AU2006269261A1 (en)	2007-01-18
CA3228910A1 (en)	2007-01-18
KR101232201B1 (ko)	2013-02-12
HUE031731T2 (en)	2017-07-28
IL188545A (en)	2011-08-31
DK2236151T3 (da)	2012-07-09
JP2015232003A (ja)	2015-12-24
JP5965520B2 (ja)	2016-08-03
PT2548568T (pt)	2018-03-21
CA2793119C (en)	2019-07-23
FR21C1060I2 (fr)	2022-12-02
US20180105557A1 (en)	2018-04-19
KR20100016120A (ko)	2010-02-12
PL2236151T3 (pl)	2012-10-31
DK3354273T3 (da)	2021-06-28
ES2386862T3 (es)	2012-09-03
PT3354273T (pt)	2021-06-28
PL2286825T3 (pl)	2017-06-30
CA2614615A1 (en)	2007-01-18
IL188545A0 (en)	2008-04-13
RU2439079C2 (ru)	2012-01-10
PL2548568T3 (pl)	2018-06-29
WO2007008704A3 (en)	2007-10-11
CN101257916A (zh)	2008-09-03
NL301150I2 (nl)	2022-11-24
IL201732A0 (en)	2010-06-16
US20170240595A1 (en)	2017-08-24
JP2009500427A (ja)	2009-01-08
NL301150I1 (sl)	2021-12-08
EP2286825B1 (en)	2016-09-28
US20220127305A1 (en)	2022-04-28
HK1258965A1 (zh)	2019-11-22
EP3925614A2 (en)	2021-12-22
SG163585A1 (en)	2010-08-30
AU2009230799B2 (en)	2012-02-09
EP3925614A3 (en)	2022-03-23
FR21C1060I1 (fr)	2022-01-21
US9850280B2 (en)	2017-12-26
HUS2100054I1 (hu)	2021-12-28
ES2604328T3 (es)	2017-03-06
DK2548568T3 (en)	2018-03-12
JP2013253090A (ja)	2013-12-19
EP2548568A2 (en)	2013-01-23
US8039435B2 (en)	2011-10-18
KR100997177B1 (ko)	2010-11-29
IL246392A (en)	2017-07-31
ES2663916T3 (es)	2018-04-17
KR20080049711A (ko)	2008-06-04
CN101676298A (zh)	2010-03-24
PT2236151E (pt)	2012-07-02
CN105837661A (zh)	2016-08-10
EP2236151B1 (en)	2012-05-23
JP2010090130A (ja)	2010-04-22
EP2286825A2 (en)	2011-02-23
US20100279922A1 (en)	2010-11-04
CA2793119A1 (en)	2007-01-18
PL3354273T3 (pl)	2021-10-11
CA3044795A1 (en)	2007-01-18
EP2548568B1 (en)	2018-01-10
EP2548568A3 (en)	2013-07-17
CN103755786B (zh)	2016-05-11
US20160368962A1 (en)	2016-12-22
HUE037147T2 (hu)	2018-08-28
CN103755786A (zh)	2014-04-30
IL201732A (en)	2016-07-31
AU2006269261B2 (en)	2009-12-17
US20110183886A1 (en)	2011-07-28
WO2007008704A2 (en)	2007-01-18
EP1915167A2 (en)	2008-04-30
ES2877349T3 (es)	2021-11-16
HUE055154T2 (hu)	2021-11-29
US9458195B2 (en)	2016-10-04
NZ565217A (en)	2010-03-26
RU2380372C2 (ru)	2010-01-27
US20180305406A1 (en)	2018-10-25
US20200095281A1 (en)	2020-03-26
RU2008104803A (ru)	2009-08-20
NZ580806A (en)	2012-07-27
DK2286825T3 (en)	2017-01-09
RU2009131092A (ru)	2011-02-20
PT2286825T (pt)	2017-01-02
CN101257916B (zh)	2013-04-03
HK1149190A1 (en)	2011-09-30
JP5889513B2 (ja)	2016-03-22
EP2236151A1 (en)	2010-10-06
EP2286825A3 (en)	2011-07-27
EP1915167A4 (en)	2010-04-07
EP3354273A1 (en)	2018-08-01
AU2009230799A1 (en)	2009-11-19
CA2614615C (en)	2012-10-16
EP3354273B1 (en)	2021-03-24
JP4734411B2 (ja)	2011-07-27

Publication	Publication Date	Title
HUS2100054I1 (hu)	2021-12-28	Melanokortin receptor ligandumok
IL188544A0 (en)	2008-04-13	Ligands of melanocortin receptors
EP1872421A4 (en)	2011-11-09	MEANS FOR CONNECTING TERMINALS
GB0505941D0 (en)	2005-04-27	Human-to-mobile interfaces
ZA200801743B (en)	2008-11-26	Intermediate bracket
IL189265A0 (en)	2008-08-07	Ferrocene-diphosphine ligands
EP1869271A4 (en)	2015-01-14	SUPPORT
GB0624987D0 (en)	2007-01-24	Novel aminoguanidines as melanocortin receptor ligands
GB0613762D0 (en)	2006-08-23	Slabline structure
GB0516946D0 (en)	2005-09-28	Receptor
GB0602684D0 (en)	2006-03-22	Bracket
GB2418125B (en)	2006-09-20	Saddle cover
GB0521122D0 (en)	2005-11-23	Mat
GB0510253D0 (en)	2005-06-29	Receptor
GB0522077D0 (en)	2005-12-07	Receptor
GB0522394D0 (en)	2005-12-14	Receptor
GB0522484D0 (en)	2005-12-14	Receptor
GB0519308D0 (en)	2005-11-02	Bracket
AU305162S (en)	2006-01-30	Bracket
AU305163S (en)	2006-01-30	Bracket
AU307179S (en)	2006-06-02	Bracket
GB0514990D0 (en)	2005-08-24	Mats
TWM291769U (en)	2006-06-11	Ant-slip mat
GB0516849D0 (en)	2005-09-21	Attachment means
GB0506820D0 (en)	2005-05-11	Saddles